MetaCap

Inhibikase Therapeutics Statistics

NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.32+0.02 (+1.54%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Inhibikase Therapeutics by the numbers

Inhibikase Therapeutics has a market capitalization of $185.2 million based on 140.27M shares outstanding. With trailing EPS of $-0.40, Inhibikase Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 26.3% below its 50-day average and 31.4% below its 200-day average.

Average daily trading volume is 584.27K shares, or about $771,238 in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

IKT valuation vs. peer median

IKT compared with the median of 8 peer companies
MetricIKTPeer medianDifference
Market cap$185.16M$191.06M-3%
Avg. volume584.27K1.22M-52%

Peer median across 8 companies: ARTV, CGEN, LCTX, CABA, IPSC, PALI, ALLO, STRO.

Valuation

Price and trading

Previous close
1.30
Open
1.28
Day range
1.28 – 1.37
52-week range
1.28 – 2.61
52-week change
-11.41%
Beta
—
Volume
1.11M

Dividends and events

Annual dividend
None
Next earnings date
Nov 10, 2026

Additional statistics

Market Cap
185.16M
Forward Pe
-3.32
Eps
-0.40
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
2.61
Week52 Low
1.28
Avg Volume
584.27K
Shares Outstanding
140.27M
Ma50
1.79
Ma200
1.93
Earnings Date
Nov 10, 2026
Pct From52w High
-49.43%
Pct From52w Low
3.13%

Related